Form 4: Windtree Therapeutics CEO Acquires Series C Preferred Stock and Warrants in Private Placement

Windtree Therapeutics' CEO, Craig Fraser, acquired 19 shares of Series C Convertible Preferred Stock and 4,011 warrants in a private placement.

Summary

• On July 22, 2024, Craig Fraser, the President and CEO of Windtree Therapeutics, acquired 19 shares of Series C Convertible Preferred Stock and 4,011 warrants.
• The acquisition was part of a private placement by the Issuer pursuant to a Securities Purchase Agreement dated July 18, 2024.
• The Series C Preferred Stock has a stated value of $1,000 per share and a conversion price of $3.74 per share.
• The warrants allow the purchase of 4,011 shares of Windtree's common stock at an exercise price of $4.11 per share.
• The warrants become exercisable six months and one day after the issuance date and expire five years after the initial exercisability date.

Sentiment

Score: 7

Explanation: The CEO's purchase of stock and warrants is generally a positive signal, suggesting confidence in the company's prospects. However, the impact is limited as it's a relatively small transaction.

Positives

• The CEO's investment in Series C Preferred Stock and warrants could signal confidence in the company's future prospects.

Risks

• The exercise of warrants could dilute existing shareholders' equity.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by the CEO is generally viewed positively.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive sign.
• The exercise of warrants could potentially dilute existing shareholders.

Key Dates

Keywords

Windtree Therapeutics, Craig Fraser, Series C Preferred Stock, Warrants, Private Placement, SEC Form 4, Beneficial Ownership